The whole ship has been steered away to the easier path for...

First 681 Last

Share
Profile

Follow
Bluegumnuts

7,033 Posts.

875

20/07/24

16:25

Post #: 74841355
Share

Originally posted by Mason14: ↑

All the P1s were completed and are published in peer reviewed journals. OV therapy is not known for toxicity, but very well known for a lack of efficacy. The lack of toxicity is in part due to the majority of administrations being done intratumorally as well as just generally being poor cytotoxic agents.

Once again. CF33 is not special.
Well, Prof Von Hoff built a career from his original work on Bisantrene. Drugs developed >40 years ago are a massive part of oncology today. Many of the drugs Bisantrene outperforms in vitro are still commonly used today as well as those used for R/R AML. There are accounts of Bisantrene curing two French girls, so I'd say it's about as real as it gets.

There are also 2 P2 trials from the last 5 years that proves the drug still works in very poor prognosis patients alone and in combination with other drugs. Clofarabine and Fludarabine are both rated severely cardiotoxic by the FDA, and there were 0 cardiac events. I've presented considerable evidence to support the notion that this data, along with the enormity of the historic literature, provides circumstantial proof that Bisantrene can provide cardioprotection while also improving the efficacy of Doxorubicin. These mechanisms of action are novel and are therefore of high value.

Brother, you really should get off your high horse, accept you made a bad call, and read what I am showing you. I am trying to help you.

Expand

The whole ship has been steered away to the easier path for revenue and whatever other reasons they have decided to go that way….. If there was a true case to completely wipe out AML and beat Doxo I am sure RAC would go this way but you are up against the FDA cartel where you are given very poor subjects to treat and your data above stating 50% CR and 70% ORR just is not true for you trials run to date for RAC which is why people are here

Pulling up old 80s data does nothing to excite me! The cardiovascular protection does but see the cost of it is where I draw my questions moving forward.

The orphan drug status is for the back up plan if it fails heart protection or a competitor comes in cheaper than $20k a pop

As for CF33 in vitro wipe all cancer cell lines but for now it is still in trials for combination therapy still kicking goals but this isn’t the thread for that…

RAC Price at posting: $1.83 Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Making money: How many microcaps should be in an investor's portfolio?

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

SCT

Scout proposes 'merger of equals' with US home security providers Roo Inc

DXB

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study